Cargando…

Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction

Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakawa, Yasuaki, Tazawa, Hiroshi, Hasei, Joe, Osaki, Shuhei, Omori, Toshinori, Sugiu, Kazuhisa, Komatsubara, Tadashi, Uotani, Kouji, Fujiwara, Tomohiro, Yoshida, Aki, Kunisada, Toshiyuki, Urata, Yasuo, Kagawa, Shunsuke, Ozaki, Toshifumi, Fujiwara, Toshiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581539/
https://www.ncbi.nlm.nih.gov/pubmed/28685948
http://dx.doi.org/10.1111/cas.13316
_version_ 1783261070232649728
author Yamakawa, Yasuaki
Tazawa, Hiroshi
Hasei, Joe
Osaki, Shuhei
Omori, Toshinori
Sugiu, Kazuhisa
Komatsubara, Tadashi
Uotani, Kouji
Fujiwara, Tomohiro
Yoshida, Aki
Kunisada, Toshiyuki
Urata, Yasuo
Kagawa, Shunsuke
Ozaki, Toshifumi
Fujiwara, Toshiyoshi
author_facet Yamakawa, Yasuaki
Tazawa, Hiroshi
Hasei, Joe
Osaki, Shuhei
Omori, Toshinori
Sugiu, Kazuhisa
Komatsubara, Tadashi
Uotani, Kouji
Fujiwara, Tomohiro
Yoshida, Aki
Kunisada, Toshiyuki
Urata, Yasuo
Kagawa, Shunsuke
Ozaki, Toshifumi
Fujiwara, Toshiyoshi
author_sort Yamakawa, Yasuaki
collection PubMed
description Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP‐301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP‐301 and ZOL in monotherapy or combination therapy was assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS‐2). The cytotoxic effect of OBP‐301 and/or ZOL was measured by assay of cell apoptosis. The effect of OBP‐301 and ZOL on osteoclast activation was investigated. The potential of combination therapy against tumor growth and bone destruction was analyzed using an orthotopic 143B osteosarcoma xenograft tumor model. OBP‐301 and ZOL decreased the viability of human osteosarcoma cells. Combination therapy with OBP‐301 and ZOL displayed a synergistic antitumor effect, in which OBP‐301 promoted apoptosis through suppression of anti‐apoptotic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited tumor‐mediated osteoclast activation, tumor growth and bone destruction compared to monotherapy. These results suggest that combination therapy of OBP‐301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and osteoclast activation.
format Online
Article
Text
id pubmed-5581539
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55815392017-09-06 Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction Yamakawa, Yasuaki Tazawa, Hiroshi Hasei, Joe Osaki, Shuhei Omori, Toshinori Sugiu, Kazuhisa Komatsubara, Tadashi Uotani, Kouji Fujiwara, Tomohiro Yoshida, Aki Kunisada, Toshiyuki Urata, Yasuo Kagawa, Shunsuke Ozaki, Toshifumi Fujiwara, Toshiyoshi Cancer Sci Original Articles Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP‐301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP‐301 and ZOL in monotherapy or combination therapy was assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS‐2). The cytotoxic effect of OBP‐301 and/or ZOL was measured by assay of cell apoptosis. The effect of OBP‐301 and ZOL on osteoclast activation was investigated. The potential of combination therapy against tumor growth and bone destruction was analyzed using an orthotopic 143B osteosarcoma xenograft tumor model. OBP‐301 and ZOL decreased the viability of human osteosarcoma cells. Combination therapy with OBP‐301 and ZOL displayed a synergistic antitumor effect, in which OBP‐301 promoted apoptosis through suppression of anti‐apoptotic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited tumor‐mediated osteoclast activation, tumor growth and bone destruction compared to monotherapy. These results suggest that combination therapy of OBP‐301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and osteoclast activation. John Wiley and Sons Inc. 2017-08-03 2017-09 /pmc/articles/PMC5581539/ /pubmed/28685948 http://dx.doi.org/10.1111/cas.13316 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Yamakawa, Yasuaki
Tazawa, Hiroshi
Hasei, Joe
Osaki, Shuhei
Omori, Toshinori
Sugiu, Kazuhisa
Komatsubara, Tadashi
Uotani, Kouji
Fujiwara, Tomohiro
Yoshida, Aki
Kunisada, Toshiyuki
Urata, Yasuo
Kagawa, Shunsuke
Ozaki, Toshifumi
Fujiwara, Toshiyoshi
Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title_full Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title_fullStr Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title_full_unstemmed Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title_short Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
title_sort role of zoledronic acid in oncolytic virotherapy: promotion of antitumor effect and prevention of bone destruction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581539/
https://www.ncbi.nlm.nih.gov/pubmed/28685948
http://dx.doi.org/10.1111/cas.13316
work_keys_str_mv AT yamakawayasuaki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT tazawahiroshi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT haseijoe roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT osakishuhei roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT omoritoshinori roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT sugiukazuhisa roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT komatsubaratadashi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT uotanikouji roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT fujiwaratomohiro roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT yoshidaaki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT kunisadatoshiyuki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT uratayasuo roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT kagawashunsuke roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT ozakitoshifumi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction
AT fujiwaratoshiyoshi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction